| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Jul 2016 | Jul 2017 | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.79K | 290 | 16.89K | 18.74K | 18.74K | 19.44K | 19.39K | 20.49K | 82.58K | 107.34K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -1.79K | -290 | -16.89K | -18.74K | -18.74K | -19.44K | -19.39K | -20.49K | -82.58K | -107.34K |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 0.84% | -57.26% | -0.11% | 0% | -0.04% | 0% | -0.06% | -3.03% | -0.3% |
| Operating Expenses | 1.67M | 2.58M | 5.41M | -946K | 3.92M | 6.97M | -3.39K | 23.27M | 32.73M | 27.2M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 942.02K | 876.16K | -1.05M | -932K | -1.37M | -3.67M | 7.27M | 7.94M | 5.97M | 5.93M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 723.43K | 1.71M | 2.39M | 3.74M | 2.22M | 1.31M | 8.02M | 15.34M | 26.75M | 21.27M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1.37K | 233 | -313K | -3.75M | -64.39K | -1.33M | -15.29M | 0 | 0 | 0 |
| Operating Income | -1.67M | -2.58M | -3.82M | 946.42K | -3.94M | -6.97M | -15.29M | -23.27M | -32.81M | -27.39M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -0.16% | -0.55% | -0.48% | 1.25% | -5.16% | -0.77% | -1.19% | -0.52% | -0.41% | 0.17% |
| EBITDA | -1.67M | -2.58M | -3.8M | 965.17K | -3.92M | -6.95M | -15.27M | -23.26M | -32.73M | -27.28M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -0.16% | -0.55% | -0.47% | 1.25% | -5.06% | -0.77% | -1.2% | -0.52% | -0.41% | 0.17% |
| D&A (Non-Cash Add-back) | 1.79K | 290 | 16.89K | 18.74K | 18.74K | 19.44K | 19.39K | 15.27K | 82.58K | 107.34K |
| EBIT | -2.21M | -3.22M | -5.39M | -5.76M | -4.91M | -17.51M | -34.07M | -27.24M | -4.85M | -26.7M |
| Net Interest Income | 0 | 0 | -3.36K | -14.69K | -26.95K | -42.95K | 135.75K | 891.21K | 283.51K | 83.53K |
| Interest Income | 3.63K | 5.16K | 12.27K | 9.13K | 39 | 3.15K | 136.73K | 891.21K | 283.51K | 120.76K |
| Interest Expense | 3.63K | 5.16K | 15.63K | 23.82K | 29.48K | 46.09K | 979 | 0 | 0 | 37.23K |
| Other Income/Expense | -37.59K | -2.48K | -436K | 905.3K | -78.9K | -6.77M | -11.69M | 2.97M | 27.95M | 652.99K |
| Pretax Income | -2.21M | -3.22M | -5.41M | -6.23M | -5.39M | -13.82M | -34.37M | -26.77M | -4.85M | -26.73M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 29.24K | 1.99K | -319K | 343.74K | -72.25K | 6.58M | 30.73K | -153K | 0 | 0 |
| Effective Tax Rate % | 0.77% | 0.8% | -0.2% | -0.1% | -0.26% | 0.21% | 0.34% | 0.76% | 0.97% | 0.99% |
| Net Income | -1.7M | -2.58M | 1.06M | 602.68K | 1.39M | -2.9M | -11.58M | -20.3M | -4.72M | -26.49M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 0.37% | -0.52% | 1.41% | -0.43% | 1.3% | -3.09% | -3% | -0.75% | 0.77% | -4.62% |
| Net Income (Continuing) | -2.21M | -3.22M | -5.41M | -5.79M | -4.94M | -17.61M | -34.07M | -27.24M | -4.85M | -26.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -302.52K | -546.79K |
| EPS (Diluted) | -5.88 | -7.32 | 2.49 | 1.04 | -5.64 | -0.19 | -1.73 | -1.74 | -42.99 | -62.60 |
| EPS Growth % | 0.45% | -0.24% | 1.34% | -0.58% | -6.42% | 0.97% | -8.11% | -0.01% | -23.71% | -0.46% |
| EPS (Basic) | -5.88 | -7.61 | 2.49 | 1.04 | -5.64 | -0.19 | -1.73 | -1.74 | -42.99 | -62.60 |
| Diluted Shares Outstanding | 288.44K | 352.98K | 427.81K | 579.66K | 713.89K | 15.27M | 15.52M | 15.62M | 109.7K | 423.11K |
| Basic Shares Outstanding | 288.44K | 339.71K | 427.81K | 579.66K | 713.89K | 15.27M | 15.49M | 15.62M | 109.7K | 423.11K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jul 2016 | Jul 2017 | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 833.35K | 1.63M | 1.88M | 157.46K | 239.43K | 57.8M | 42.35M | 26.95M | 3.65M | 19.93M |
| Cash & Short-Term Investments | 820.6K | 1.62M | 1.75M | 146.71K | 19.46K | 57.27M | 41.04M | 21.25M | 862.09K | 17.87M |
| Cash Only | 131.58K | 1.01M | 720.26K | 146.71K | 19.46K | 57.27M | 41.04M | 21.25M | 862.09K | 10.49M |
| Short-Term Investments | 689.02K | 601.76K | 1.03M | 0 | 0 | 0 | 0 | 0 | 0 | 7.37M |
| Accounts Receivable | 2.67K | 5.6K | 0 | 2.82K | 0 | 12.57K | 24.1K | 717.74K | 1.37M | 563.6K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 1 | 0 | 8.1K | 199.03K | 516.23K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 0.09 | 1.06 | - | 157.68 | 3.88K | 9.69K | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.36K |
| Total Non-Current Assets | 2.35K | 1.91K | 407.5K | 257.98K | 238.88K | 245.61K | 230.34K | 215.07K | 2.22M | 1.72M |
| Property, Plant & Equipment | 449 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 388.18K | 296.82K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1 | 1 | 274.73K | 257.97K | 238.88K | 245.61K | 230.34K | 215.07K | 199.8K | 184.53K |
| Long-Term Investments | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 418.49K | 523.17K |
| Other Non-Current Assets | 1.9K | 1.9K | 132.76K | 0 | 1 | 0 | 0 | 0 | 1.21M | 718.62K |
| Total Assets | 835.7K | 1.64M | 2.28M | 415.43K | 478.31K | 58.04M | 42.58M | 27.16M | 5.87M | 21.65M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -0.35% | 0.96% | 0.4% | -0.82% | 0.15% | 120.35% | -0.27% | -0.36% | -0.78% | 2.69% |
| Total Current Liabilities | 48.59K | 885.9K | 1.34M | 1.06M | 3.63M | 556.79K | 941.09K | 1.8M | 7.46M | 3.98M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 214.12K | 463.28K | 1.12M | 7.17M | 3.28M |
| Days Payables Outstanding | - | - | - | - | - | 4.02K | 8.72K | 20.02K | 31.69K | 11.14K |
| Short-Term Debt | 0 | 0 | 1.12M | 301.33K | 228.75K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 506.91K | 0 | -1.07K | -4.25K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 48.59K | 379K | 219.28K | 756.52K | 3.4M | 0 | 0 | 0 | 0 | 701.24K |
| Current Ratio | 17.15x | 1.84x | 1.40x | 0.15x | 0.07x | 103.81x | 45.00x | 14.96x | 0.49x | 5.01x |
| Quick Ratio | 17.15x | 1.84x | 1.40x | 0.14x | 0.01x | 102.88x | 45.00x | 14.96x | 0.49x | 5.01x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 142.8K | 225.44K | 31.31M | 29.14M | 1.1M | 337.67K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 25.99K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -191.78K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 199.46K | 31.31M | 29.14M | 1.1M | 337.67K |
| Total Liabilities | 48.59K | 885.9K | 1.34M | 1.06M | 3.77M | 782.24K | 32.25M | 30.94M | 8.56M | 4.32M |
| Total Debt | 0 | 0 | 1.12M | 301.33K | 228.75K | 25.99K | 0 | 0 | 0 | 0 |
| Net Debt | -131.58K | -1.01M | 400.4K | 154.62K | 209.29K | -57.24M | -41.04M | -21.25M | -862.09K | -10.49M |
| Debt / Equity | - | - | 1.19x | - | - | 0.00x | - | - | - | - |
| Debt / EBITDA | - | - | - | 0.31x | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | 0.16x | - | - | - | - | - | - |
| Interest Coverage | -459.52x | -500.66x | -244.35x | 39.74x | -133.62x | -151.27x | -15616.96x | - | - | -735.70x |
| Total Equity | 787.11K | 750.23K | 945.02K | -643.49K | -3.29M | 57.26M | 10.33M | -3.78M | -2.68M | 16.79M |
| Equity Growth % | -0.32% | -0.05% | 0.26% | -1.68% | -4.12% | 18.38% | -0.82% | -1.37% | 0.29% | 7.25% |
| Book Value per Share | 2.73 | 2.13 | 2.21 | -1.11 | -4.61 | 3.75 | 0.67 | -0.24 | -24.48 | 39.68 |
| Total Shareholders' Equity | 787.11K | 750.23K | 945.02K | -643.49K | -3.29M | 57.26M | 10.33M | -3.78M | -2.38M | 17.33M |
| Common Stock | 4.49M | 6.61M | 7.84M | 10.38M | 11.23M | 54.78M | 65.59M | 69.59M | 72.17M | 101.52M |
| Retained Earnings | -4.27M | -6.68M | -9.74M | -13.78M | -16.64M | -15.75M | -60.35M | -80.65M | -85.44M | -111.76M |
| Treasury Stock | 0 | 0 | 3.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.62M | 2.13M | -80.98K | -94.53K | -127K | -138.68K | -138.68K | -138.68K | -138.68K | -138.68K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -302.52K | -546.79K |
| Jul 2016 | Jul 2017 | Jul 2018 | Jul 2019 | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.2M | -1.54M | -3.81M | -3.87M | -1.16M | -7.75M | -12.48M | -23.74M | -24.13M | -28.17M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -0.28% | -0.28% | -1.48% | -0.02% | 0.7% | -5.68% | -0.61% | -0.9% | -0.02% | -0.17% |
| Net Income | -1.7M | -2.58M | -4.15M | -4.4M | -3.69M | -428.33K | -26.84M | -20.3M | -4.93M | -26.56M |
| Depreciation & Amortization | 907 | 233 | 12.97K | 14.25K | 13.97K | 15.26K | 15.27K | 15.27K | 83.9K | 106.63K |
| Stock-Based Compensation | 496.21K | 218.25K | 365.49K | 46.08K | 1.69K | 1.97M | 3.07M | 2.19M | 1.8M | 776.88K |
| Deferred Taxes | 0 | 0 | 1 | 1 | 0 | -8.86M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 21.39K | 276.09K | 328.55K | -319.86K | 64.65K | 1.84M | 11.66M | -2.12M | -28.14M | -577.9K |
| Working Capital Changes | -22.03K | 830.37K | -358.51K | 787.9K | 2.45M | -2.28M | -391.29K | -3.53M | 7.05M | -1.92M |
| Change in Receivables | 24.38K | -2.8K | -11.99K | 17 | -30 | 12 | -15 | 7 | -732.58K | 738.52K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 15 | -7 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | -1.41M | 249.16K | 660.46K | 6.05M | -3.91M |
| Cash from Investing | 158.78K | 120.35K | -453.63K | 1.02M | 0 | 0 | 0 | 0 | -681.8K | -7.65M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -456.8K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 158.78K | 120.35K | 0 | 1.02M | 0 | 0 | 0 | 0 | 0 | -330K |
| Cash from Financing | 801.9K | 2.32M | 4.06M | 2.28M | 1.08M | 65M | -3.74M | 3.95M | 4.42M | 45.45M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 71.33K | -572.71K | 1.45M | 671.18K | 268.28K | 13.7M | 6.43M | 1.59K | 0 | -303.23K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -1.2M | -1.54M | -3.81M | -3.87M | -1.16M | -7.75M | -12.48M | -23.74M | -24.58M | -28.17M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -0.28% | -0.28% | -1.48% | -0.02% | 0.7% | -5.68% | -0.61% | -0.9% | -0.04% | -0.15% |
| FCF per Share | -4.16 | -4.35 | -8.90 | -6.68 | -1.62 | -0.51 | -0.80 | -1.52 | -224.09 | -66.58 |
| FCF Conversion (FCF/Net Income) | 0.71x | 0.59x | -3.57x | -6.43x | -0.84x | 2.68x | 1.08x | 1.17x | 5.12x | 1.06x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -174.25% | -336.18% | 125.65% | 399.75% | - | -10.73% | -34.27% | -619.74% | - | -375.65% |
| Return on Invested Capital (ROIC) | -171.56% | -989.94% | -529.86% | 165.74% | - | -27782.35% | - | - | - | -1495.75% |
| Debt / Equity | - | - | 1.19x | - | - | 0.00x | - | - | - | - |
| Interest Coverage | -459.52x | -500.66x | -244.35x | 39.74x | -133.62x | -151.27x | -15616.96x | - | - | -735.70x |
| FCF Conversion | 0.71x | 0.59x | -3.57x | -6.43x | -0.84x | 2.68x | 1.08x | 1.17x | 5.12x | 1.06x |
BriaCell Therapeutics Corp. (BCTXW) grew revenue by 0.0% over the past year. Growth has been modest.
BriaCell Therapeutics Corp. (BCTXW) reported a net loss of $26.2M for fiscal year 2025.
BriaCell Therapeutics Corp. (BCTXW) has a return on equity (ROE) of -375.6%. Negative ROE indicates the company is unprofitable.
BriaCell Therapeutics Corp. (BCTXW) had negative free cash flow of $28.2M in fiscal year 2025, likely due to heavy capital investments.